access
Senate puts forward bipartisan bill to lower price of drugs
July 24, 2019Research and Development PBMs, Senate, USA, access, bipartisan, pharma, pricing
The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs. …
Prices hiked on 3,400 drugs in first half of 2019
July 4, 2019Research and Development, Sales and Marketing abstruse, access, generics, pharma, prescription, pricing
There have been price hikes on more than 3,400 drugs in the United States in the first six months of …
MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK
June 11, 2019Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing
MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …
UK government refuses to sign up to WHO pricing transparency resolution
May 29, 2019Research and Development WHA, WHO, access, health UK, pharma, pricing
The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …
Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy
May 28, 2019Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma
The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
ICR calls for faster access to innovative cancer drugs
April 25, 2019Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing
The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK. The call …
Médecins Sans Frontières (MSF)/ Doctors Without Borders calls on CEPI to revise ‘toothless’ access policy
March 6, 2019Sales and Marketing CEPI, MSF, access, public health, tokyo, vaccines
The humanitarian organisation Médecins Sans Frontières (MSF) has called on The Coalition for Epidemic Preparedness Innovations (CEPI) to revise their …
Pharmacists warn of shortages in England
January 18, 2019Medical Communications access, pharmacists, pricing, shortages
Pharmacists in England have warned that they are struggling to obtain many common generic medicines, as the number of medicines …
Sanders calls on Trump to support drug pricing bill
January 11, 2019Medical Communications Bernie Sanders, Trump, access, pharma, pricing
Senator Bernie Sanders has called on President Donald Trump to support new legislation aimed at cutting prices on prescription drugs. …
NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma
December 7, 2018Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …
GSK retain top spot on access to medicines list
November 22, 2018Business Services, Research and Development GSK, J&J, JJ, R&D, Sanofi, access, low and middle income countries, researh
The majority (63%) of research and development projects are being conducted by just five companies; GSK, Johnson & Johnson, Sanofi, …
Trump administration propose ruling requiring price transparency on TV ads
October 16, 2018Manufacturing and Production Alex Azar, Drug pricing, Trump, access, adverts
US Health and Human Services Secretary Alex Azar, has announced a proposal which would require pharma firms to include the …
NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process
September 25, 2018Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …
J&J pledges to end global TB pandemic
September 25, 2018Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis
Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …
Latest content
FibroFind appoints Lee Borthwick as CEO
